Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Mesitran versus vaginal estrogen for pessary-associated vaginal ulceration
NL-OMON57231Recruiting
- Sponsor
- Zuyderland
- Start
- May 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Revamil and estriol in Vaginal ulcer and vaginal mucosal injury (2 arms), sponsored by Zuyderland. Primary endpoints: Vaginal mucosa damage at 6 weeks and Stage of vaginal mucosal disturbance. Started May 2026; status: recruiting.
02
Drugs
Revamilestriol
03
Conditions
Vaginal ulcervaginal mucosal injury
Beyond the preview
Go deeper on NL-OMON57231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57231.